Vincerx Pharma Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Ahmed Hamdy
Chief executive officer
US$735.0k
Total compensation
| CEO salary percentage | 65.2% |
| CEO tenure | 4yrs |
| CEO ownership | 5.1% |
| Management average tenure | 3.6yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely
Aug 21
Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Jul 18Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Mar 30Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Sep 22Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?
Jun 24Vincerx Pharma doses first patient in early-stage VIP152 cancer study
Jun 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$27m |
| Jun 30 2024 | n/a | n/a | -US$28m |
| Mar 31 2024 | n/a | n/a | -US$38m |
| Dec 31 2023 | US$735k | US$479k | -US$40m |
| Sep 30 2023 | n/a | n/a | -US$46m |
| Jun 30 2023 | n/a | n/a | -US$54m |
| Mar 31 2023 | n/a | n/a | -US$61m |
| Dec 31 2022 | US$1m | US$460k | -US$63m |
| Sep 30 2022 | n/a | n/a | -US$58m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$49m |
| Dec 31 2021 | US$615k | US$460k | -US$39m |
| Sep 30 2021 | n/a | n/a | -US$49m |
| Jun 30 2021 | n/a | n/a | -US$25m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$622k | US$15k | -US$17m |
Compensation vs Market: Ahmed's total compensation ($USD734.95K) is about average for companies of similar size in the US market ($USD646.54K).
Compensation vs Earnings: Ahmed's compensation has been consistent with company performance over the past year.
CEO
Ahmed Hamdy (59 yo)
4yrs
Tenure
US$734,953
Compensation
Dr. Ahmed M. Hamdy, M.D., is Co-Founder of Vincerx Pharma, Inc. (formerly known as Vincera Pharma, Inc.) and has been its Chief Executive Officer and Chairman of the Board since December 2020. He served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 4yrs | US$734.95k | 5.11% $ 332.6k | |
| Co-Founder | 4yrs | US$668.96k | 0.26% $ 16.7k | |
| Chief Financial Officer | 4yrs | US$565.67k | 0.11% $ 7.4k | |
| Founder | 3.8yrs | US$3.16m | no data | |
| Founder & Chairman of Scientific Advisory Board | no data | no data | 4.82% $ 313.9k | |
| Chief Scientific Officer | 3.8yrs | no data | no data | |
| Vice President of Investor Relations & Corporate Communications and Chief of Staff | 1.4yrs | no data | no data | |
| Vice President of Quality Operations & Compliance | 1.9yrs | no data | no data | |
| Senior Director of People & Culture and Head of Human Resource | 3.3yrs | no data | no data | |
| Executive Chief Development Officer | 3.6yrs | no data | no data | |
| Chief Business Officer | 1.5yrs | no data | no data | |
| VP of Biologics Development and Manufacturing and Sr. VP of Chemistry & Manufacturing | 1.5yrs | no data | no data |
3.6yrs
Average Tenure
59yo
Average Age
Experienced Management: VINC's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 4yrs | US$734.95k | 5.11% $ 332.6k | |
| Co-Founder | 4yrs | US$668.96k | 0.26% $ 16.7k | |
| Founder & Chairman of Scientific Advisory Board | 3.7yrs | no data | 4.82% $ 313.9k | |
| Independent Director | 4yrs | US$69.14k | 0% $ 0 | |
| Independent Director | 4yrs | US$47.89k | 0.16% $ 10.6k | |
| Member of Scientific Advisory Board | 3.7yrs | no data | no data | |
| Independent Director | 4yrs | US$52.89k | 0.057% $ 3.7k | |
| Independent Director | 3.6yrs | US$47.89k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.7yrs | no data | no data | |
| Independent Director | 4yrs | US$47.89k | 0.0024% $ 154.9 |
3.8yrs
Average Tenure
57yo
Average Age
Experienced Board: VINC's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 03:02 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vincerx Pharma, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| Michael King | H.C. Wainwright & Co. |
| I-Eh Jen | Laidlaw & Company (UK) Ltd |